Repligen Corp (RGEN) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

Repligen Reports Third Quarter 2024 Financial Results

Third quarter reported revenue of $155 million, an increase of 10% year-over-yearCDMO revenue and orders both...

Repligen Corporation to Present at Upcoming Investor Conferences

WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company...